British drug-maker GlaxoSmithKline (GSK) has submitted a marketing authorisation application to the European Medicines Agency (EMA) seeking an additional indication for eltrombopag (Revolade).
Press Releases is unique and effective promotional tool offered from Worldpharmatoday.com aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.
To add free press releases please click here.
Cologne, Germany, November 12, 2014 / B3C newswire / -New Oncology announced today that it has entered into a collaboration with the National Cancer Centre Singapore (NCCS). Under this agreement, New Oncology will apply its proprietary diagnostic platform ‘NEO’ that enables physicians to select optimal targeted therapies for their patients. NEO provides a fully informative molecular cancer profile from the smallest quantities of patient samples with short turn-around times. No financial details were disclosed.
Zurich, Switzerland, November 10, 2014 / B3C newswire / - Haselmeier was able to successfully grow over the past few years, allowing the company to carve out a solid position in the market for medical devices. In keeping with this progress, the Haselmeier Group has restructured its management organisation to ensure this forward momentum continues successfully. The company has introduced a Group Executive Board tasked with coordination and decision-making for all Haselmeier locations. The Group Executive Board will ensure consistent, effective management of the Haselmeier sites, thereby coordinating the group's strategy.
Novasep and partner Nilsan Nishotech to install the first continuous chromatography system at Laurus Labs
Novasep Varicol high-performance continuous chromatography technology brings productivity gains in an Indian-based API commercial production
Valbonne, France, November 7, 2014. – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Damian Marron, CEO, TxCell, will present at the 2nd Annual EU Advanced Therapies Investor Day in London. The presentation is scheduled for Thursday, November 13, 2014 at 10:30 a.m. at 30 Euston Square, London, NW1 2FB, United Kingdom.
TxCell (FR0010127662 - TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today reports its revenues(1) as of September 30, 2014.
CARLINA Technologies signs a partnership agreement with GenBiotech to develop a sustained-release protein formulation for cartilage repair
CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed.
GTx Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's third quarter 2014 financial results on Monday November 10 at 9:00 a.m. Eastern Time. The call and webcast will follow the release of the financial results earlier that day.
Neurocrine Biosciences to Present at the Nomura Biotechnology ConferenceLive Audio Webcast will be on November 6 2014
TxCell to present on T Cellular Therapy for Autoimmune Diseases at the 7th National Bio-Therapy Conference 2014, China
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China.
Page 1 of 65